CN Patent

CN101505754A — 包括三唑并[4,5-d]嘧啶衍生物的适于口服给药的组合物

Assigned to AstraZeneca AB · Expires 2009-08-12 · 17y expired

What this patent protects

本发明涉及药物组合物，更特别地，涉及一种含有下述化合物的药物组合物：{1S－[1α，2α，3β(1S * ，2R * )，5β]}－3－(7－{[2－(3，4－二氟苯基)环丙基]氨基}－5－(丙硫基)－3H－1，2，3－三唑并[4，5－d]嘧啶－3－基)－5－(2－羟基乙氧基)环戊烷－1，2－二醇。

USPTO Abstract

本发明涉及药物组合物，更特别地，涉及一种含有下述化合物的药物组合物：{1S－[1α，2α，3β(1S * ，2R * )，5β]}－3－(7－{[2－(3，4－二氟苯基)环丙基]氨基}－5－(丙硫基)－3H－1，2，3－三唑并[4，5－d]嘧啶－3－基)－5－(2－羟基乙氧基)环戊烷－1，2－二醇。

Drugs covered by this patent

Patent Metadata

Patent number
CN101505754A
Jurisdiction
CN
Classification
—
Expires
2009-08-12
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.